ANGLE PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.79 GBX | -4.57% |
|
+25.89% | +25.89% |
| Apr. 24 | No record close for FTSE 100; mixed trade in US | AN |
| Apr. 24 | No record close for FTSE 100; mixed trade in US | AN |
| Sales 2023 * | 2.08M 2.6M | Sales 2024 * | 7.61M 9.51M | Capitalization | 40.37M 50.45M |
|---|---|---|---|---|---|
| Net income 2023 * | -19M -23.74M | Net income 2024 * | -14M -17.49M | EV / Sales 2023 * | 13.4 x |
| Net cash position 2023 * | 12.56M 15.7M | Net cash position 2024 * | 1.6M 2M | EV / Sales 2024 * | 5.09 x |
| P/E ratio 2023 * |
-2.06
x | P/E ratio 2024 * |
-2.74
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 89.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on ANGLE plc
More press releases
| 1 day | +26.53% | ||
| 1 week | +26.53% | ||
| Current month | +24.00% | ||
| 1 month | +10.71% | ||
| 3 months | -4.62% | ||
| 6 months | +37.78% | ||
| Current year | +31.91% |
1 week
11.26
17.63
1 month
11.2617.63
Current year
11.2637.40
1 year
9.0737.40
3 years
9.07163.75
5 years
9.07163.75
10 years
9.07163.75
| Managers | Title | Age | Since |
|---|---|---|---|
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Griffiths
DFI | Director of Finance/CFO | - | 94-12-31 |
Andrew Newland
FOU | Founder | 63 | 94-03-31 |
Brian Howlett
BRD | Director/Board Member | 80 | 13-01-06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 14.79 | -4.57% | 1 341 406 |
| 24-04-24 | 15.5 | +26.53% | 12,615,900 |
| 24-04-23 | 12.25 | -2.00% | 553,192 |
| 24-04-22 | 12.5 | +4.17% | 1,029,292 |
| 24-04-19 | 12 | +2.13% | 1,308,627 |
Delayed Quote London S.E., April 24, 2024 at 11:35 am EDT
More quotes
ANGLE plc is a United Kingdom-based liquid biopsy company. The Company is engaged in the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy-non-invasive cancer diagnostics. Its platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplexed analysis of nucleic acids and proteins. Its Parsortix PC1 Clinical system captures and harvests circulating CTCs from metastatic breast cancer patients blood for subsequent, user-validated analysis. The Parsortix PC1 Clinical System is a liquid biopsy technology. Its labs in Guildford provide specialist CTC enrichment and analysis services to support translational research studies and pharmaceutical trials. It has developed the Parsortix system, including instruments and one-time use cassettes that can be sold to third-party laboratories for their use in research, pharmaceutical development, or clinical use.
Calendar
2024-04-24
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.155
GBP
Average target price
0.685
GBP
Spread / Average Target
+341.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.91% | 50.19M | |
| -12.06% | 19.18B | |
| -44.61% | 2.73B | |
| +16.10% | 1.84B | |
| -3.24% | 1.61B | |
| +20.19% | 1.18B | |
| -21.52% | 898M | |
| -8.03% | 710M | |
| -16.68% | 694M | |
| +13.21% | 526M |
- Stock Market
- Equities
- AGL Stock
